Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's BIIB Alzheimer's drug Aduhelm and other amyloid-targeted drugs to just patients participating in clinical trials.

"Monoclonal antibodies directed against amyloid that FDA approves for Alzheimer's disease based upon evidence of efficacy from a change in a surrogate endpoint (e.g., amyloid reduction) considered as reasonably likely to predict clinical benefit may be covered in a randomized controlled trial conducted under an investigational new drug (IND) application," CMS said in its final decision summary.

For drugs similar to Aduhelm, the CMS said it would allow coverage if the medication is approved after a standard review by the FDA.

Related: CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply.

Part of that modification means that CMS will not require a separate randomized controlled trial that duplicates an RCT conducted for the FDA's accelerated approval. Biogen already agreed on a protocol.

"This unprecedented CMS decision effectively denies all Medicare beneficiaries access to Aduhelm, the first and only FDA-approved therapy in a new class of Alzheimer's drugs. It may also limit coverage for any future approved treatment in the class," Biogen said.

Read Next: Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks.

"When additional data from this new class of treatments become available, Biogen urges CMS to reconsider today's decision for all FDA-approved amyloid-beta targeting therapies," the Company added.

Price Action: BIIB shares closed at $211.64 on Thursday.

photo via Pixabay

Posted In: AduhelmAlzheimer's diseaseAlzheimer’sBiotechGovernmentNewsHealth CareTop StoriesGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.